DelveInsight, a leading market research and consulting firm, announces the release of its latest report, “Diabetic Neuropathy Market Insights, Epidemiology, and Market Forecast–2036.” The report provides an in-depth understanding of Diabetic Neuropathy, including historical and forecasted epidemiology, market trends, treatment landscape, emerging therapies, market size, market share, and industry outlook across the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.
Key Takeaways from the Diabetic Neuropathy Market
The Diabetic Neuropathy market size across the 7MM is expected to grow significantly during the forecast period 2022–2036.
The United States accounted for the largest Diabetic Neuropathy market share among the 7MM and is expected to maintain its dominance throughout the forecast period.
The Diabetic Neuropathy market size in the United States was estimated at approximately USD 2.7 billion in 2025 and is projected to reach nearly USD 7.1 billion by 2036, reflecting substantial market expansion.
According to the International Diabetes Federation (IDF), more than 43 million adults in the United States are affected by diabetes, creating a substantial patient pool at risk of developing diabetic neuropathy.
Secondary epidemiological sources indicate that diabetic neuropathy affects more than 30% of individuals with diabetes in Japan, highlighting a considerable disease burden.
According to secondary research, approximately 32% of individuals with diabetes in Italy are affected by diabetic neuropathy.
DelveInsight estimates indicate that diagnosed prevalent cases of Diabetic Neuropathy continue to increase across the 7MM, driven by rising diabetes prevalence and aging populations.
In the United States, females account for approximately 60% of diagnosed diabetic neuropathy cases, while males represent approximately 40%.
Leading Diabetic Neuropathy companies such as Vertex Pharmaceuticals, Lexicon Pharmaceuticals, Grünenthal, Collegium Pharmaceuticals, and others are actively advancing novel therapies to improve patient outcomes.
Promising Diabetic Neuropathy drugs in development include Pilavapadin (LX9211) and JOURNAVX (Suzetrigine).
Keen to know more about the market? Request our sample page at Diabetic Neuropathy Market Report. https://www.delveinsight.com/sample-request/diabetic-neuropathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr
Key Factors Driving the Diabetic Neuropathy Market
Rising Prevalence of Diabetes Mellitus
The increasing global prevalence of Type 1 and Type 2 diabetes continues to be the primary driver of the Diabetic Neuropathy market. As the diabetic patient population expands, the number of individuals developing diabetic neuropathy is expected to increase substantially, creating significant demand for effective treatments.
Growing Need for Effective Neuropathic Pain Management
Diabetic neuropathy is associated with chronic pain, sensory loss, motor dysfunction, and autonomic complications that significantly impact quality of life. Current treatment options focus primarily on symptom management, creating a strong demand for therapies that provide improved pain relief and functional benefits.
Emergence of Novel Disease-Modifying Therapies
Current approved therapies mainly address neuropathic pain without reversing underlying nerve damage. Emerging therapies targeting ion channels, neuroinflammation, nerve repair pathways, and neuronal protection are expected to transform the Diabetic Neuropathy drug market and address longstanding unmet clinical needs.
Increasing Healthcare Expenditure and Early Diagnosis
Growing healthcare investments, improved screening programs, and increasing awareness among healthcare professionals are supporting earlier diagnosis and treatment initiation, further contributing to Diabetic Neuropathy market growth.
Diabetic Neuropathy Competitive Landscape
The current Diabetic Neuropathy treatment market remains largely focused on symptomatic relief, as no approved therapies directly reverse nerve damage or halt disease progression. Existing treatment approaches primarily include glycemic control, pain management, physical therapy, and preventive care.
Among approved therapies, QUTENZA (capsaicin) from Grünenthal and NUCYNTA ER (tapentadol) from Collegium Pharmaceuticals represent key marketed products for neuropathic pain management associated with diabetic peripheral neuropathy.
The emerging Diabetic Neuropathy pipeline is led by innovative therapies such as Pilavapadin (LX9211) from Lexicon Pharmaceuticals and JOURNAVX (Suzetrigine) from Vertex Pharmaceuticals. These therapies target novel mechanisms including AAK1 inhibition and selective NaV1.8 inhibition, potentially offering differentiated efficacy and safety profiles compared to current treatment options.
Discover more about therapies set to grab major Diabetic Neuropathy market share @ Diabetic Neuropathy Treatment Landscape
Recent Developments in the Diabetic Neuropathy Market
In November 2025, Lexicon Pharmaceuticals announced that it had scheduled an End-of-Phase II meeting with the US FDA and disclosed ongoing partnership discussions related to Pilavapadin.
According to presentations at the 44th Annual J.P. Morgan Healthcare Conference, Pilavapadin is expected to advance into Phase III clinical development.
In November 2024, Lexicon Pharmaceuticals completed enrollment in the Phase IIb PROGRESS trial evaluating Pilavapadin for diabetic peripheral neuropathic pain.
JOURNAVX (Suzetrigine) continues Phase III clinical development, with enrollment expected to be completed by the end of 2026.
Suzetrigine has received Breakthrough Therapy Designation (BTD) from the US FDA for the treatment of pain associated with diabetic peripheral neuropathy.
What is Diabetic Neuropathy?
Diabetic Neuropathy is a chronic and progressive complication of diabetes caused by prolonged hyperglycemia-induced nerve damage. The condition primarily affects peripheral nerves but may also involve autonomic and motor nerves. Symptoms commonly include numbness, tingling, burning sensations, stabbing pain, muscle weakness, balance impairment, and autonomic dysfunction such as orthostatic hypotension and gastroparesis. Diabetic Neuropathy significantly impacts quality of life and remains one of the most common long-term complications of diabetes.
Diabetic Neuropathy Epidemiology Segmentation
The Diabetic Neuropathy epidemiology section provides insights into historical and forecasted patient populations across the 7MM and includes:
Total Diagnosed Prevalent Cases of Diabetes Mellitus
Total Diagnosed Prevalent Cases of Diabetic Neuropathy
Gender-specific Diagnosed Prevalent Cases of Diabetic Neuropathy
Treated Cases of Diabetic Neuropathy
Country-specific Patient Population Analysis
Scope of the Diabetic Neuropathy Market Report
Therapeutic Assessment: Diabetic Neuropathy marketed and emerging therapies
Diabetic Neuropathy Market Dynamics: Key market drivers, barriers, opportunities, and future trends
Key Companies: Vertex Pharmaceuticals, Lexicon Pharmaceuticals, Grünenthal, Collegium Pharmaceuticals, and others
Key Therapies: JOURNAVX (Suzetrigine), Pilavapadin (LX9211), QUTENZA (Capsaicin), NUCYNTA ER (Tapentadol), and others
Competitive Intelligence Analysis: SWOT analysis and market entry strategies
Diabetic Neuropathy Market Size, Market Share, Treatment Trends, and Industry Outlook
Unmet Needs, KOL Views, Analyst Perspectives, Market Access, and Reimbursement Analysis
To know more about Diabetic Neuropathy companies working in the treatment market, visit @ Diabetic Neuropathy Clinical Trials and Therapeutic AssessmentTable of Contents
Diabetic Neuropathy Market Report Introduction
Executive Summary for Diabetic Neuropathy
SWOT Analysis of Diabetic Neuropathy
Diabetic Neuropathy Patient Share (%) Overview at a Glance
Diabetic Neuropathy Market Overview at a Glance
Diabetic Neuropathy Disease Background and Overview
Diabetic Neuropathy Epidemiology and Patient Population
Country-Specific Patient Population of Diabetic Neuropathy
Diabetic Neuropathy Current Treatment and Medical Practices
Diabetic Neuropathy Unmet Needs
Diabetic Neuropathy Emerging Therapies
Diabetic Neuropathy Market Outlook
Country-Wise Diabetic Neuropathy Market Analysis (2022–2036)
Diabetic Neuropathy Market Access and Reimbursement
Diabetic Neuropathy Market Drivers
Diabetic Neuropathy Market Barriers
Diabetic Neuropathy Appendix
Diabetic Neuropathy Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kirti SharmaEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
